All In Biotech

NDA 216352 · Luye Innomind Pharma

Erzofri

Paliperidone Palmitate · Intramuscular

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 26, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 2 recruiting

FAERS reports

3,421

3,270 serious, 484 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA- RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ERZOFRI is not approved for use in patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ERZOFRI is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Mar 9, 2026.

ERZOFRI is indicated for the treatment of: Schizophrenia in adults . Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants . ERZOFRI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 ) Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants. ( 1 )

Mechanism: Paliperidone palmitate is hydrolyzed to paliperidone [see Clinical Pharmacology (12.3) ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone in the listed indications is unclear. However, the drug's effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2) and serotonin Type 2 (5HT 2A ) receptor antagonism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 26, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
6 products under this application
  • ERZOFRI · PALIPERIDONE PALMITATE 117MG/0.75ML (117MG/0.75ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ERZOFRI · PALIPERIDONE PALMITATE 39MG/0.25ML (39MG/0.25ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ERZOFRI · PALIPERIDONE PALMITATE 351MG/2.25ML (156MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ERZOFRI · PALIPERIDONE PALMITATE 156MG/ML (156MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ERZOFRI · PALIPERIDONE PALMITATE 78MG/0.5ML (78MG/0.5ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ERZOFRI · PALIPERIDONE PALMITATE 234MG/1.5ML (156MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Paliperidone Palmitate" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hospitalisation429
  • drug ineffective329
  • schizophrenia269
  • death256
  • suicide attempt253
  • off label use252
  • dyskinesia232
  • sedation223
  • sexual dysfunction210
  • dystonia201
  • condition aggravated199
  • blood glucose increased195

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20071
20081
20095
20107
201115
201276
201374
201449
201533
201646
201773
2018120
2019173
2020136
2021195
2022650
2023551
2024482
2025393
2026339

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 135 on PubMed

Sponsor: Luye Innomind Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.